Skip to main content

Mortality Following Long-Acting Injectable Antipsychotics Use in Patients with Dementia: An Inverse Probability of Treatment Weighting Analysis

    Basic Details
    Date Posted
    In progress
    Medical Product
    long-acting injectable antipsychotics
    Health Outcome(s)

    In this analysis, we described counts of new users of long-acting injectable antipsychotics (LAIAs) including paliperidone palmitate, risperidone microspheres, and haloperidol decanoate in the Sentinel Distributed Database (SDD). We estimated the two-week or four-week risk of mortality comparing (1) paliperidone palmitate users to risperidone microspheres users and (2) paliperidone palmitate users to haloperidol decanoate users. The study period included data from January 1, 2010 through June 30, 2022. We distributed this request to one Sentinel Data Partner on March 6, 2023. 

    The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.

    Additional Details
    FDA Center
    Time Period
    January 1, 2010 - June 30, 2022
    Analysis Type
    Retrospective Inferential
    Population / Cohort
    Individuals 18 years of age and older
    Data Sources
    Sentinel Distributed Database (SDD)